SEC Form 13F Summary: GSK Plc
Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by GSK Plc, reporting its holdings of equity securities as of the period ending June 30, 2026. The document details the specific issuers, share counts, and voting authority held by the company.
Key Financial Metrics and Holdings
The filing lists 13 equity positions, primarily concentrated in the biotechnology and pharmaceutical sectors. The total value of these specific reported holdings is approximately $478.5 million. Key positions include:
- Wave Life Sciences Ltd: 18,245,691 shares valued at $106,007,465.
- Vir Biotechnology Inc: 8,550,954 shares valued at $87,134,221.
- BioNTech SE: 889,824 shares valued at $82,798,123.
- CRISPR Therapeutics AG: 3,220,627 shares valued at $175,652,997.
All listed positions are held with sole voting authority. The filing does not provide data on GSK Plc's overall revenue, profit, cash flow, debt, or liquidity, as Form 13F is limited to reporting specific equity holdings.
Material Changes
The filing text does not provide comparative data from a prior period; therefore, material changes in holdings versus the previous quarter cannot be determined from this document alone.
Guidance, Outlook, and Risks
This document contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory disclosure of investment holdings only.
Investor Verification Checklist
- Verify the total aggregate value of GSK Plc's investment portfolio beyond the 13 positions listed here.
- Confirm if any of these holdings represent strategic partnerships or licensing agreements with the underlying biotech firms.
- Check subsequent filings to determine if these positions were maintained, increased, or liquidated in the following quarter.
- Review GSK Plc's primary financial statements (10-K or 20-F) for comprehensive revenue and profit metrics, as they are absent in this 13F filing.